To investigate the expression characteristics, clinical prognostic significance, immune microenvironment correlation of zinc finger protein ZNF322 in glioblastoma (GBM), as well as its effect on the biological functions of GBM cells.
The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were used to analyze the expression differences of ZNF322 in glioma and GBM tissues and its relationship with patient prognosis. Kaplan-Meier survival curves, univariate and multivariate Cox regression analyses were performed to evaluate the prognostic value of ZNF322. Single-cell transcriptome data (GSE162631) were analyzed to determine the distribution characteristics of ZNF322 in malignant cell subpopulations of GBM. The CIBERSORTx algorithm was used to assess the correlation between ZNF322 expression and immune cell infiltration. ZNF322 knockdown and overexpression models were established in U87MG cells. CCK-8 assay, wound healing assay, and flow cytometry were used to detect cell proliferation, migration, and cell cycle changes, respectively.
The expression level of ZNF322 in glioma and GBM tissues was significantly higher than that in normal brain tissue (P < 0.05), and its high expression was significantly associated with adverse clinical-pathological features such as WHO grading, mutational status of isocitrate dehydrogenase, and histological type (all P < 0.01). Univariate and multivariate Cox regression analyses demonstrated that high ZNF322 expression was an independent prognostic risk factor for GBM patients (HR=1.51, 95%CI: 1.15-1.99, P=0.003). Kaplan-Meier survival curves confirmed that patients with high ZNF322 expression had significantly shorter overall survival compared to those with low expression (P < 0.01). Single-cell transcriptome analysis revealed that ZNF322 was predominantly enriched in malignant cell subpopulations resembling oligodendrocytes-like and oligodendrocyte progenitors-like. Immunohistochemical infiltration analysis showed that ZNF322 exhibited negative correlations with immune cells such as natural killer cells and dendritic cells, suggesting its involvement in the remodeling of the GBM immune microenvironment. Functional enrichment analysis indicated that upregulated ZNF322 was significantly enriched in pathways related to chromosome segregation and cell cycle, whereas downregulated ZNF322 was enriched in pathways involving synaptic signaling regulation and neurotransmitter transport. In vitro, ZNF322 knockdown inhibited U87MG cell proliferation and migration and induced G0/G1-phase arrest; overexpression produced the opposite effects and increased the proportion of cells in G2/M phase.
ZNF322 is highly expressed in GBM and is closely associated with poor patient prognosis. It may participate in the malignant progression of GBM by regulating the cell cycle and immune microenvironment. ZNF322 has the potential to serve as a prognostic biomarker and a molecular therapeutic target for GBM.
京公网安备11010802044758号